Cancer Treatment Today

There are several phase II studies suggesting activity Xalkori (crizotinib) for clear cell sarcoma. Shoffski 2019 did a prospective study that showed that the PFS with crizotinib in MET+CCSA is similar to results achieved first-line in non-selected metastatic soft tissue sarcomas with single-agent doxorubicin. r The PFS is similar to results achieved with pazopanib in previously treated sarcoma patients. There is evidence of its effectiveness also fo inflammatory myofibroblastic tumors (IMFT).

Schöffski PA et al, ctivity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial ‘A.nn Oncol. 2017 Dec 1;28(12):3000-3008.
Schöffski P et al, Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’.Ann Oncol. 2019 Feb 1;30(2):344.

Schöffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear cell sarcoma (CCSA) with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 CREATE. Presented at: CTOS 2018 Annual Meeting; Rome, Italy: November 14-17. Paper 018.

Schöffski P, Sufliarsky J, Gelderblom H, et al. Prospective trial of crizotinib (C) in patients (PTS) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alternations: EORTC phase 2 study 90101 “CREATE.” Presented at: CTOS 2018 Annual Meeting; Rome, Italy: November 14-17. Paper 01
.
Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018;6(6):431-441.